Durvalumab with or without Olaparib for people with endometrial cancer in Korea
Official title: Durvalumab With or Without Olaparib in Patients With Endometrial Cancers Regulatory Post Marketing Surveillance
Run by AstraZeneca · NCT06995833 · Data updated 2026-11-12
This study will see if Durvalumab, with or without Olaparib, is safe and works for people in Korea who are prescribed these drugs for endometrial cancer as part of routine care.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | AstraZeneca Industry-sponsored |
| Drugs / interventions | Durvalumab |
| Locations | 1 site (Seoul) |
| Status | Recruiting |
| Started | September 19, 2025 |
| Main results expected | June 29, 2029 |
| Study ends | June 29, 2029 |
| Registry record updated | September 2, 2026 |
| Trial ID | NCT06995833 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults in Korea who are prescribed Durvalumab with or without Olaparib according to the approved Korean label and who can provide informed consent.
✕Probably not a fit
Patients receiving these drugs for off-label indications, those enrolled in concurrent interventional trials, or people treated outside participating Korean centers are unlikely to gain relevant information from this observational program.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a multicenter, prospective, observational real-world study enrolling about 50 patients in Korea and following them for roughly 12 months after the first dose or up to 90 days after stopping treatment. Patients will be identified and included while receiving Durvalumab with or without Olaparib as prescribed by their treating clinicians under the approved Korean label. The primary focus is on safety monitoring, with secondary analyses of effectiveness and exploratory comparisons by treatment and mismatch repair (MMR) status. The overall study period is expected to run for four years from the product approval date in Korea.
Why it matters
Potential benefit: If successful, the study could provide clinicians and patients with clearer, real-world information on the safety and effectiveness of these treatments in Korean patients with endometrial cancer.
How similar studies have gone: Some clinical trials combining PD-(L)1 inhibitors with PARP inhibitors have shown promising signals in gynecologic cancers, but robust real-world evidence specifically in endometrial cancer remains limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients eligible for the study drug according to the approved label in Korea 2. Provision of a signed and dated written informed consent by the patient or their legally acceptable representative Exclusion Criteria: 1. Participation in any concurrent interventional trials during the period of the study drug treatment 2. Other off-label indications according to the approved label in Korea
Where it's running
-
Research Site
Seoul, South Korea Recruiting
Study contacts
- Study coordinator: AstraZeneca Clinical Study Information Center
- Email: information.center@astrazeneca.com
- Phone: 1-877-240-9479
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Examining the effectiveness and safety of Durvalumab and Olaparib in endometrial cancer patients
This study is testing how well and safely a combination of Durvalumab and Olaparib works for women with advanced or recurrent endometrial cancer who are receiving specific first-line treatments.
-
Evaluating immunotherapy for colorectal and endometrial cancer
This study is testing a new immunotherapy treatment for people with colorectal or endometrial cancer to see if a combination of two drugs can help them better than just one.
-
Personalized navigation to support rural and Black women with endometrial cancer
This pilot tests a tailored patient-navigation program to help rural and Black patients with endometrial cancer access care and services.
-
Neoadjuvant trastuzumab, durvalumab, and FLOT for HER2-positive gastric or GEJ cancer
This study tests a pre-surgery treatment combining trastuzumab, durvalumab, and FLOT for patients with HER2-positive locally advanced gastric or gastroesophageal junction cancer to see how many achieve complete tumor disappearance.
-
CR-002 study in adults with advanced solid tumors
This trial tests CR-002 as a single therapy to see if it is safe and tolerable in adults with locally advanced or metastatic solid tumors
-
Methylation markers in self-samples to help detect gynecological cancers
This study tests whether self-collected urine and vaginal samples can reveal DNA methylation or other genetic markers that indicate endometrial, ovarian, vulvar, or vaginal cancers in women who are at risk or have postmenopausal bleeding.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.